REG - Silence Therapeutics - Total Voting Rights

Silence TherapeuticsAnnouncement

08/10/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211008:nRSH4314Oa&default-theme=true

RNS Number : 4314O  Silence Therapeutics PLC  08 October 2021

 

Additional listing and Total Voting Rights

8 October 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the
Company"), a leader in the discovery, development and delivery of novel short
interfering ribonucleic acid (siRNA) therapeutics for the treatment of
diseases with significant unmet medical need, in conformity with
the Disclosure Rules and Transparency Rules, provision 5.6.1, today
notified the market of the following:

The Company's issued share capital consists of 89,777,000 Ordinary Shares
of 5p each with voting rights. The Company does not hold any shares in
Treasury.

The above figure of 89,777,000 may be used by shareholders as the denominator
for the calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the Company under
the FCA's Disclosure and Transparency Rules.

 

Enquiries

 Silence Therapeutics plc                                           Tel:  +1 (646) 637-3208

 Gem Hopkins, Head of IR and Corporate Communications

 ir@silence-therapeutics.com (mailto:ir@silence-therapeutics.com)

   Investec Bank plc (Nominated Adviser and Broker)                   Tel:  +44 (0) 20 7597 5970

 Daniel Adams/Gary Clarence

 European PR                                                        Tel: +44 (0) 20 3709 5700

 Consilium Strategic Communications

 Mary-Jane Elliott/ Angela Gray / Chris Welsh

 silencetherapeutics@consilium-comms.com
 (mailto:silencetherapeutics@consilium-comms.com)

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing
the body's natural mechanism of RNA interference, or RNAi, to inhibit the
expression of specific target genes thought to play a role in the pathology of
diseases with significant unmet medical need. Silence's proprietary messenger
RNAi GOLD™ platform can be used to create siRNAs that precisely target and
silence disease-associated genes in the liver, which represents a substantial
opportunity. Silence's wholly owned product candidates include SLN360 designed
to address the high and prevalent unmet medical need in reducing
cardiovascular risk in people born with high levels of lipoprotein(a) and
SLN124 designed to address iron loading anemias. Silence also maintains
ongoing research and development collaborations with AstraZeneca, Mallinckrodt
Pharmaceuticals, and Takeda, among others. For more information, please visit
https://www.silence-therapeutics.com/ (https://www.silence-therapeutics.com/)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVREAFEXEAKFFAA